Company Overview of Five Prime Therapeutics, Inc.
Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of protein therapeutics that block cancer and inflammatory disease processes. The company’s product candidates include FP-1039/GSK3052230, a protein therapeutic, which is in Phase 1b clinical trials for trapping and neutralizing cancer-promoting fibroblast growth factors (FGFs) involved in cancer cell proliferation and new blood vessel formation; FPA008, a Phase 1 clinical trial stage antibody that inhibits colony stimulating factor-1 receptor; and FPA144 is an antibody for inhibiting FGF receptor 2b, as well as to treat patients with gastric cancer and potentially other solid tumo...
Two Corporate Drive
South San Francisco, CA 94080
Founded in 2001
Key Executives for Five Prime Therapeutics, Inc.
Total Annual Compensation: $525.0K
Chief Business Officer
Total Annual Compensation: $362.8K
Chief Medical Officer and Senior Vice President
Total Annual Compensation: $350.0K
Senior Vice President
Total Annual Compensation: $311.9K
Compensation as of Fiscal Year 2013.
Five Prime Therapeutics, Inc. Key Developments
Five Prime Therapeutics, Inc Appoints Robert Sikorski as Vice President of Global Clinical Development
Sep 17 14
Five Prime Therapeutics, Inc. announced the appointment of Robert Sikorski, M.D., Ph.D., as Vice President of Global Clinical Development. Dr. Sikorski will oversee the global clinical development activities for company's product candidates. Dr. Sikorski joins company from MedImmune where he was Senior Director, Global Oncology Research and Development. Prior to that, he was Director, Global Oncology Research and Development at Amgen, where he led the development of several oncology drug candidates.
GlaxoSmithKline Exercises Option for a Commercial License to a Novel Muscle Disease Target
Sep 15 14
Five Prime Therapeutics, Inc. announced that GlaxoSmithKline (GSK) has exercised its option to obtain an exclusive, worldwide license to products containing or directed to an undisclosed muscle disease target that Five Prime discovered using its proprietary library of human extracellular proteins and target screening and discovery capabilities. By exercising its option, GSK will receive exclusive rights to develop and commercialize products globally, at its own cost and expense, that incorporate or are directed to the selected target. Five Prime will receive a payment of $1.5 million in connection with the option exercise and is entitled to receive up to $122.5 million in preclinical, development and commercial-related milestone payments and royalties in the low- to mid-single-digit range on net sales of products related to the target.
Five Prime Therapeutics, Inc. Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-09-2014 05:15 PM
Sep 3 14
Five Prime Therapeutics, Inc. Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-09-2014 05:15 PM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Lewis T. Williams, Founder, Chief Executive Officer, President and Director.
Similar Private Companies By Industry
Recent Private Companies Transactions
March 19, 2014